

# Ennio Lubrano Di Scorpaniello

## List of Publications by Citations

**Source:**

<https://exaly.com/author-pdf/569276/ennio-lubrano-di-scorpaniello-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136  
papers

3,014  
citations

29  
h-index

50  
g-index

151  
ext. papers

3,622  
ext. citations

4.1  
avg, IF

5.13  
L-index

#	Paper	IF	Citations
136	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1060-71	9.5	485
135	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 986-91	2.4	192
134	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1167-70	4.1	144
133	Drug-induced lupus erythematosus. <i>Autoimmunity</i> , <b>2005</b> , 38, 507-18	3	105
132	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management.	13.6	84
131	Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 898-903	4.1	82
130	Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 849-55	4.1	75
129	Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. <i>Clinical Rheumatology</i> , <b>2010</b> , 29, 399-403	3.9	65
128	Qualifying unmet needs and improving standards of care in psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1759-66	4.7	57
127	Remission in ankylosing spondylitis treated with anti-TNF- $\alpha$ drugs: a national multicentre study. <i>Rheumatology</i> , <b>2013</b> , 52, 1914-9	3.9	52
126	Fibromyalgia in patients with irritable bowel syndrome. An association with the severity of the intestinal disorder. <i>International Journal of Colorectal Disease</i> , <b>2001</b> , 16, 211-5	3	52
125	Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. <i>Clinical and Experimental Rheumatology</i> , <b>2011</b> , 29, S28-41	2.2	50
124	Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF- $\alpha$ Drugs. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 350-5	4.1	49
123	An ultrasonographic study of enthesitis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment. <i>Rheumatology International</i> , <b>2016</b> , 36, 1579-1583	3.6	47
122	The Sex Influence on Response to Tumor Necrosis Factor- $\alpha$ Inhibitors and Remission in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , <b>2017</b> ,	4.1	42
121	Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 6-13	4.1	38
120	Simple clinical indicators for early psoriatic arthritis detection. <i>SpringerPlus</i> , <b>2014</b> , 3, 759		37

119	Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1006-11	4.1	37
118	Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 918-23	4.1	36
117	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 201-208	2.4	35
116	Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor- $\alpha$ drugs: an Italian multicenter study. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 258-63	4.1	33
115	Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2015</b> , 44, 542-550	5.3	32
114	The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. <i>Clinical Rheumatology</i> , <b>2011</b> , 30, 1063-7	3.9	32
113	Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis. <i>Drugs</i> , <b>2016</b> , 76, 663-73	12.1	30
112	Secukinumab for ankylosing spondylitis and psoriatic arthritis. <i>Therapeutics and Clinical Risk Management</i> , <b>2016</b> , 12, 1587-1592	2.9	30
111	Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1159-1164	4.1	29
110	Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. <i>Rheumatology</i> , <b>2010</b> , 49, 1107-11	3.9	29
109	Updated guidelines for the management of axial disease in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2286-9	4.1	27
108	Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2332-8	4.1	26
107	Current evidence in the field of the management with TNF- $\alpha$ inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 641-50	5.4	26
106	Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 934-5	2.4	26
105	Effects of a combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: a pilot study. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 2029-34	4.1	26
104	Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up. <i>Clinical Rehabilitation</i> , <b>2014</b> , 28, 562-72	3.3	25
103	The Sex Influence on Response to Tumor Necrosis Factor- $\alpha$ Inhibitors and Remission in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 195-201	4.1	23
102	The Definition and Measurement of Axial Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2015</b> , 93, 40-2		22

101	Progress in understanding and utilizing TNF- $\alpha$ inhibition for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 315-31	5.1	22
100	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 864-74	13.6	22
99	Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients. <i>Archives of Dermatological Research</i> , <b>2012</b> , 304, 719-26	3.3	22
98	The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. <i>Clinical and Experimental Rheumatology</i> , <b>2011</b> , 29, 80-4	2.2	22
97	Deterioration in Anthropometric Measures over Six Years in Patients with Ankylosing Spondylitis. <i>Physiotherapy</i> , <b>1999</b> , 85, 138-143	3	21
96	Effectiveness of rehabilitation in active ankylosing spondylitis assessed by the ASAS response criteria. <i>Rheumatology</i> , <b>2007</b> , 46, 1672-5	3.9	20
95	Beyond the joint: Subclinical atherosclerosis in rheumatoid arthritis. <i>World Journal of Orthopedics</i> , <b>2014</b> , 5, 328-35	2.2	19
94	Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 991-1010	2.2	19
93	Unmet Needs in Axial Spondyloarthritis. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2018</b> , 55, 332-339	12.3	18
92	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1772-1779	4.7	17
91	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 856-860	4.7	17
90	Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 1027-32	3.9	16
89	What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 38-42	4.1	16
88	Role of comorbidities in spondyloarthritis including psoriatic arthritis. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 3-10	3.9	15
87	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and ExpertsSConsensus. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102738	13.6	14
86	New Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A Review. <i>Rheumatology and Therapy</i> , <b>2019</b> , 6, 479-486	4.4	13
85	Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists?. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 455-8	4.7	13
84	Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. <i>International Journal of Rheumatic Diseases</i> , <b>2016</b> , 19, 799-805	2.3	13

83	Psoriatic Disease: Clinical Staging. <i>Journal of rheumatology Supplement, The</i> , <b>2015</b> , 93, 24-6		12
82	The radiological assessment of axial involvement in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2012</b> , 89, 54-6		11
81	Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study. <i>Postgraduate Medicine</i> , <b>2016</b> , 128, 693-6	3.7	10
80	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1298-1305	3.3	10
79	Residual Disease Activity and Associated Factors in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1490-1495	4.1	10
78	To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	10
77	Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study. <i>Postgraduate Medicine</i> , <b>2018</b> , 130, 137-141	3.7	9
76	Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1541-6	4.1	9
75	Rehabilitation and surgical management of ankylosing spondylitis. <i>Musculoskeletal Surgery</i> , <b>2013</b> , 97 Suppl 2, S191-5	2.4	9
74	Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 867-882	4.4	9
73	Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study. <i>Journal of Immunology Research</i> , <b>2018</b> , 2018, 9101964	4.5	9
72	An overview of low disease activity and remission in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S51-4	2.2	9
71	The role of IL-17 in the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 815-821	5.1	8
70	New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol. <i>Journal of rheumatology Supplement, The</i> , <b>2015</b> , 93, 70-2		8
69	Pharmacoeconomic issues in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2012</b> , 89, 103-5		8
68	Multimorbidity and comorbidity in psoriatic arthritis - a perspective. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 963-972	5.1	8
67	Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 575-584	2.3	8
66	Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients. <i>Rheumatology and Therapy</i> , <b>2019</b> , 6, 521-528	4.4	7

65	The severity of irritable bowel syndrome or the presence of fibromyalgia influencing the perception of visceral and somatic stimuli. <i>BMC Gastroenterology</i> , <b>2014</b> , 14, 182	3	7
64	Rehabilitation in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2009</b> , 83, 81-2		7
63	Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	7
62	Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis?. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, S54-8	2.2	7
61	Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 68-75	2.2	7
60	Clinical remission in rheumatoid arthritis and psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 900-910	2.2	7
59	Elderly psoriatic arthritis patients on TNF-blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 1797-1802	3.9	6
58	Management and Treatment of Patients With Major Depressive Disorder and Chronic Diseases: A Multidisciplinary Approach. <i>Frontiers in Psychology</i> , <b>2020</b> , 11, 542444	3.4	6
57	Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 301-310	4.4	6
56	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , <b>2018</b> , 35, 545-562	4.1	6
55	Physicians' Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1256-1262	4.1	6
54	TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 1303-1312	5.1	6
53	A novel biological target for the treatment of psoriatic arthritis. <i>Immunotherapy</i> , <b>2014</b> , 6, 515-8	3.8	6
52	Etanercept in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2012</b> , 89, 74-6		6
51	Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1497	5.6	6
50	Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature. <i>Rheumatology</i> , <b>2018</b> , 57, vii23-vii31	3.9	6
49	Abatacept for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 899-905	5.1	6
48	Beyond anti-TNF-agents in psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2013</b> , 9, 507-9	5.1	5

47	Validity and reliability of an Italian version of the revised Leeds disability questionnaire for patients with ankylosing spondylitis. <i>Rheumatology</i> , <b>2005</b> , 44, 666-9	3.9	5
46	Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1765-6	4.1	5
45	Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	5
44	An Assessment of Hand Erosive Osteoarthritis: Correlation of Radiographic Severity with Clinical, Functional and Laboratory Findings. <i>Rheumatology and Therapy</i> , <b>2019</b> , 6, 125-133	4.4	4
43	Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk. <i>Expert Review of Clinical Immunology</i> , <b>2014</b> , 10, 307-15	5.1	4
42	New insights in occult psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2012</b> , 89, 22-3		4
41	Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 825-836	4.4	4
40	Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 2251-2262	3.9	4
39	Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement. <i>Rheumatology International</i> , <b>2018</b> , 38, 1727-1734	3.6	4
38	Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 313-316	2.2	4
37	Relationship of Psoriatic Arthritis to Other Spondyloarthritides. <i>Journal of rheumatology Supplement, The</i> , <b>2015</b> , 93, 33-5		3
36	Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs. <i>Journal of rheumatology Supplement, The</i> , <b>2015</b> , 93, 61-4		3
35	Emerging drugs for psoriatic arthritis. <i>Expert Opinion on Emerging Drugs</i> , <b>2010</b> , 15, 399-414	3.7	3
34	Gender-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study from the National Registry of the Italian Society Of Rheumatology. <i>Journal of Rheumatology</i> , <b>2021</b> ,	4.1	3
33	A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action. <i>Joint Bone Spine</i> , <b>2021</b> , 88, 105175	2.9	3
32	Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 1449-1455	3.9	2
31	Paradoxical psoriatic arthritis in a patient with psoriasis treated with guselkumab.. <i>Clinical and Experimental Dermatology</i> , <b>2021</b> ,	1.8	2
30	The Conundrum of Psoriatic Arthritis: a Pathogenetic and Clinical Pattern at the Midpoint of Autoinflammation and Autoimmunity.. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2022</b> ,	12.3	2



29	New Insights in Physical Therapy and Rehabilitation in Psoriatic Arthritis: A Review. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 639-649	4.4	2
28	Current approach to the management of psoriatic arthritis according to a sample of Italian rheumatologists. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 1051-1058	2.2	2
27	A national survey on the management of psoriatic arthritis using the Delphi method. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 214-220	2.2	2
26	Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 103, 226-227	2.2	2
25	Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 512	2.2	2
24	Rheumatology Care in the Face of COVID-19. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 425-428	4.4	1
23	Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , <b>2014</b> , 6, 7-13	2.4	1
22	Psoriatic arthritis and psoriasis projects in Italy: a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 2201-3	4.1	1
21	IL-17 inhibition could fill treatment gap in psoriatic arthritis. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e199-e200.2	4.2	1
20	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa032	1.1	1
19	Prevalence of Type 2 and Type 1 Diabetes in Psoriatic Arthritis: An Italian Study.. <i>Journal of Clinical Rheumatology</i> , <b>2022</b> , 28, e324-e329	1.1	1
18	Assessment of Widespread and Extraarticular Pain in Psoriatic Arthritis: A Case-control Study. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1405-1409	4.1	1
17	Unmet needs in outcome measures of Psoriatic Arthritis: focus on axial radiographic and nail involvement. <i>Acta Biomedica</i> , <b>2013</b> , 84, 87-93	3.2	1
16	Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 193-198	2.2	1
15	Assessment of bone morphogenetic protein 2 and interleukin-17A in patients with axial spondyloarthritis and their potential role in the new bone formation: a cross-sectional study. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 1044-1047	2.2	1
14	Therapeutic Targets for Ankylosing Spondylitis - Recent Insights and Future Prospects.. <i>Open Access Rheumatology: Research and Reviews</i> , <b>2022</b> , 14, 57-66	2.4	1
13	Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 1199-1209	5.1	0
12	The "Climb" Towards Minimal Disease Activity in Psoriatic Arthritis. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1443-1450	4.4	0



11	What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , <b>2021</b> , 60, 5292-5299	3.9	○
10	Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 737079	4.9	○
9	Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: a cross-sectional analysis.. <i>Joint Bone Spine</i> , <b>2022</b> , 105372	2.9	○
8	Occult axial involvement in patients with psoriatic arthritis mutilans: a case report. <i>Reumatismo</i> , <b>2019</b> , 71, 88-91	1.1	
7	Dr. Lubrano, reply. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 942	4.1	
6	Dactylitis and psychic stress. <i>International Journal of Clinical Rheumatology</i> , <b>2015</b> , 10, 9-11	1.5	
5	Potential Differences in Clinical Features, Disease Activity, Function and Impact of Disease Between Oligo and Polyarticular Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2021</b> , 6, 38-42	1.1	
4	Corticosteroid injection treatment for dactylitis in psoriatic arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211041864	3.8	
3	MRI Assessment of Extra-axial Findings at Pelvic Sites in a Group of Axial-SpA Patients. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1897-1904	4.4	
2	Certolizumab: efficacy and safety profile of a novel pegylated TNF-alpha blocking agent. <i>Acta Biomedica</i> , <b>2011</b> , 82, 26-34	3.2	
1	Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2022</b> , 14, 1759720X221090310	3.8	○